QIAGEN N.V. offers comprehensive sample to insight solutions that facilitate the transformation of biological materials into valuable molecular insights globally. The company provides a range of primary sample technology consumables, including nucleic acid stabilization and purification kits tailored for primary sample materials. It supports both manual and automated processing for various applications such as genotyping, gene expression analysis, and the study of viral and bacterial samples, utilizing advanced technologies like silica membranes and magnetic beads. Additionally, QIAGEN supplies secondary sample technology consumables that include kits and components for nucleic acid purification from secondary samples. The company's product offerings extend to instruments for nucleic acid purification, various accessories, and specialized assays including interferon-gamma release assays for TB testing, post-transplant testing assays, and viral load monitoring. QIAGEN also offers prenatal testing solutions, assays for detecting sexually transmitted diseases and HPV, as well as genomic variant analysis methods that identify mutations, insertions, deletions, and fusions. The sample to insight instruments feature one-step molecular analyses designed for complex syndromes and integrated PCR testing. The company provides a multitude of PCR consumables, including quantitative PCR and reverse transcription kits furthering analysis in areas like gene expression and regulation. Moreover, QIAGEN caters to human identification and forensics with STR assays, alongside food contamination testing. Its PCR instrument line includes innovative digital PCR solutions and tailored OEM consumables. Additionally, the company provides predefined and custom NGS gene panels, library preparation kits, and services for whole genome amplification, along with various bioinformatics solutions and custom laboratory services. Recently, the company reported selling, general, and administrative expenses of $583,669,000.00 indicating its operational overhead costs. Meanwhile, it recorded a net income of $424,880,000.00 which reflects its profitability. This performance is supported by an income before tax ratio of 0.23 demonstrating a solid pre-tax margin. The earnings per share (EPS) is reported at $2.04 highlighting the company's profitability on a per-share basis. Moreover, it recorded a substantial revenue of $2,089,998,999.00 underscoring its strong market presence. The stock is affordable at $45.94 making it an attractive option for budget-conscious investors. With an average trading volume of 2,170,910.00 the stock demonstrates moderate liquidity, appealing to a range of investors. Holding a mid-range market capitalization of $10,258,747,710.00 the company positions itself as a steady performer within the competitive landscape. QIAGEN is a key player in the Medical - Diagnostics & Research industry, significantly contributing to the overall market dynamics and advancements. It belongs to the Healthcare sector, where it drives innovation and fosters growth, reinforcing its role as a leader in molecular diagnostics and related fields.